英国以岭莲花清瘟胶囊可以在英国买到， 全英免费邮寄，英国存货， 全世界邮寄。
Won the Second-class Prize of the National Science and Technology Progress Award
Listed in the List of National Essential Drugs
A Class A Product in the National Health Insurance Program
A National Level Key New Product
A Key National Project for New Drug Innovation of the "Twelfth Five-Year Plan"
A Model High-tech Project of National Development and Reform Commission
Phase II Clinical Trial Underway in the US as Approved by US FDA
The pathogenesis and the treatment of influenza are investigated from the TCM point of view as guided by the collateral disease theory. A kind of treatment strategy with "Active Intervention" is proposed. Such famous recipes as the hemp apricot decoction recorded in the Treatise on Febrile Diseases of Han Dynasty, the use of rheum officinale for the treatment of epidemic diseases proposed in the Treatise on Pestilence of Ming Dynasty and the Lonicera and Forsythia Powder recorded in the Treatise on Differentiation and Treatment of Epidemic Febrile Diseases of Qing Dynasty are combined together into one recipe and it is proved to be with excellent therapeutic effects on the early symptoms of cold and influenza. It has a broad spectrum of therapeutic effects against viruses and bacteria and has such functions as anti-inflammation, fever relieving, resolving phlegm and relieving coughing. "Lianhua Qingwen is the best choice for anti-inflammation, fever relieving and anti-virus for such symptoms as headache, fever and aversion to cold and for the treatment of such diseases as cold, influenza and avian influenza". This product plays a very important role in such public health emergencies as the epidemic outbreaks of influenza, avian influenza and novel coronavirus pneumonia. It is a kind of product of reserve of the relevant national authorities.
2019, recognized as a recommended product in the Standard Therapy for Influenza (2019)
2018, recognized as a recommended product in the Standard Therapy for Influenza (2018, Revised)
2018, recognized as a recommended product in the Standard Therapy for Influenza (2018)
2017, recognized as a recommended product in Guideline for Clinical Application of TCM Patent Products · Treatment of Pediatric Diseases
2017, recognized as a recommended product in the Standard Therapy for Human Beings Infected by H7N9 Avian Influenza
2016, the Phase II Clinical Trial for Lianhua Qingwen approved by US FDA started in Virginia in the US in September
2015, recognized as a recommended product in the Expert Consensus Document on Treatment of Cold in Special Populations
2015, recognized as a recommended product in the Standard Therapy for Middle East Respiratory Syndrome
2014, recognized as a recommended product in the Standard TCM Therapy for Ebola Virus Infections
2014, recognized as a recommended product in the Standard Therapy for Human Beings Infected by H7N9 Avian Influenza
2013, recognized as a recommended product in the Expert Consensus Document on Medical Rescuing of Human Beings Infected by H7N9 Avian Influenza
2013, recognized as a recommended product in the Standard Therapy for Human Beings Infected by H7N9 Avian Influenza
2012, recognized as a recommended product in the Standard TCM Therapy for Influenza B Virus Infections
2011, recognized as a recommended product in the Guideline on Diagnosis and Treatment of Influenza
2010, recognized as a recommended product in the Standard Therapy for Rheumatic Fever (Non-severe Community Acquired Pneumonia)
2009, recognized as a recommended product in the Standard Therapy for Human Beings Infected by Influenza A H1N1
2008, recognized as a recommended product in the Instructions on Use of TCM Therapies for Prevention and Treatment of Diseases after an Earthquake
2008, recognized as a recommended product in the Standard Therapy for Human Beings Infected by Avian Influenza (2008)
2005, recognized as a recommended product in the Standard Therapy for Human Beings Infected by Avian Influenza
